Table of Contents Author Guidelines Submit a Manuscript
Mediators of Inflammation
Volume 2012, Article ID 138971, 4 pages
http://dx.doi.org/10.1155/2012/138971
Research Article

Fetuin A Concentration in the Second Trimester Amniotic Fluid of Fetuses with Trisomy 21 Appears to Be Lower: Phenotypic Considerations

12nd Department of Obstetrics and Gynecology, University of Athens Medical School, Aretaieion Hospital, 124B Vas. Sofias Avenue, 115 26 Athens, Greece
2West of Scotland Deanery, Obstetrics and Gynaecology, Glasgow, G3 8BW, UK
3Department of Hygiene, Epidemiology and Medical Statistics, University of Athens Medical School, 115 27 Athens, Greece
4Diagnostic Genetic Centre, 115 28 Athens, Greece
5Department of Pharmaceutical Technology, School of Pharmacy, University of Athens, 157 71 Athens, Greece

Received 23 July 2011; Revised 21 November 2011; Accepted 21 November 2011

Academic Editor: Teresa Zelante

Copyright © 2012 S. Iliodromiti et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Abstract

Objective. We investigated whether the concentration of the glycoprotein fetuin A is altered in the second trimester amniotic fluid of trisomy 21 pregnancies compared with euploid pregnancies. Methods. 25 pregnancies with an extra chromosome 21 were matched for maternal and gestational age with 25 pregnancies with normal karyotype. Levels of fetuin A in amniotic fluid were measured by a commercially available enzyme-linked immunosorbent assay (ELISA) kit. Results. The median concentration of fetuin A in amniotic fluid of trisomy 21 pregnancies (5.3 ng/ml) was statistically significantly lower ( 𝑃 v a l u e = 0 . 0 0 8 ) compared with that in euploid pregnancies (6.8 ng/mL). Conclusion. Lower levels of fetuin A in trisomy 21 may indicate an association with altered metabolic pathways in this early stage that could potentially be associated with features of the syndrome, such as growth restriction or impaired osteogenesis.